RxDoctor Payments DataLook up a doctor →

James Bienvenu, MD

Urology · Knoxville, TNNPI 1407167018

Payments from drug & device makers

$242,633in general payments, 2019–2025

Across 381 payments — averaging $636.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$224K
  • Ferring Pharmaceuticals Inc.$6K
  • Urogen Pharma, Inc.$4K
  • Angiodynamics, Inc.$1K
  • Boston Scientific$1K
  • Johnson & Johnson$691
  • plus $6K from 49 others

What the payments were for

  • Speaking & faculty fees$7,72342%
  • Travel & lodging$1,4848%
  • Food & beverage$9,10349%
  • Education$2111%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$242,633 in reported general payments places this provider in the 90th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$657,712
Medicare patients
826
Services billed
6,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide78$1,083,809
NubeqaDarolutamide54$711,778
ErleadaApalutamide47$684,912
OrgovyxRelugolix222$571,091
MyrbetriqMirabegron106$86,196
GemtesaVibegron52$36,267
Abiraterone Acetate24$24,328
Tamsulosin Hcl476$5,880
Finasteride172$2,122
Oxybutynin Chloride ErOxybutynin Chloride64$1,685
Estradiol19$1,494
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$519
Prednisone25$445
Ciprofloxacin Hcl42$247
Dutasteride18$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$484$1,170,005184 claims
BayerNubeqa$204$711,77854 claims
Johnson & JohnsonErleada$691$684,91247 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$384$607,358274 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$125$24,32824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 urology providers in Tennessee.

Other urology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →